The world's most valuable drugmaker hiked its full-year sales and profit guidance, despite missing lighter-than-expected first-quarter revenue.
Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March 31 rose 26% year over year to $8.77 billion, shy of the $8.92 billion expected by analysts, according to estimates compiled by LSEG.
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.'s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply.
Club Earnings Jim Cramer Investment Strategy Markets Breaking News: Markets Eli Lilly And Co Earnings Novo Nordisk A/S Novo Nordisk A/S Biogen Inc Merck & Co Inc Pfizer Inc Pharmaceuticals Business News
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentumThe Food and Drug Administration said supplies of Zepbound and Mounjaro are expected to be limited through the second quarter, for all but one dosage.
Read more »
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, MounjaroZepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Read more »
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, MounjaroZepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Read more »
Eli Lilly stock climbs on gross margin beat, raised 2024 revenue outlookEli Lilly stock climbs on gross margin beat, raised 2024 revenue outlook
Read more »
Eli Lilly, 3M, PayPal rise premarket; Coca-Cola, Tesla, McDonald's fallEli Lilly, 3M, PayPal rise premarket; Coca-Cola, Tesla, McDonald's fall
Read more »
Stocks making the biggest moves midday: Eli Lilly, 3M, PayPal, Tesla and moreThese were some of the stocks making the largest moves in trading on Tuesday.
Read more »